ATE441666T1 - Antikírper gegen den fibroblastenwachstumsfaktor 23 - Google Patents

Antikírper gegen den fibroblastenwachstumsfaktor 23

Info

Publication number
ATE441666T1
ATE441666T1 AT03701009T AT03701009T ATE441666T1 AT E441666 T1 ATE441666 T1 AT E441666T1 AT 03701009 T AT03701009 T AT 03701009T AT 03701009 T AT03701009 T AT 03701009T AT E441666 T1 ATE441666 T1 AT E441666T1
Authority
AT
Austria
Prior art keywords
ferm
amino acid
antibody
acid sequence
seq
Prior art date
Application number
AT03701009T
Other languages
English (en)
Inventor
Yuji Yamazaki
Takashi Shimada
T Yamashita
Original Assignee
Kyowa Hakko Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kirin Co Ltd filed Critical Kyowa Hakko Kirin Co Ltd
Application granted granted Critical
Publication of ATE441666T1 publication Critical patent/ATE441666T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
AT03701009T 2001-12-28 2003-01-06 Antikírper gegen den fibroblastenwachstumsfaktor 23 ATE441666T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2001401689 2001-12-28
JP2002262020 2002-09-06
PCT/JP2003/000017 WO2003057733A1 (fr) 2001-12-28 2003-01-06 Anticorps diriges contre le facteur de croissance 23 des fibroblastes

Publications (1)

Publication Number Publication Date
ATE441666T1 true ATE441666T1 (de) 2009-09-15

Family

ID=26625414

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03701009T ATE441666T1 (de) 2001-12-28 2003-01-06 Antikírper gegen den fibroblastenwachstumsfaktor 23

Country Status (11)

Country Link
US (1) US7923012B2 (de)
EP (1) EP1466925B1 (de)
JP (1) JP4527982B2 (de)
KR (1) KR101016476B1 (de)
CN (1) CN100519584C (de)
AT (1) ATE441666T1 (de)
AU (1) AU2003202472B2 (de)
CA (1) CA2471656C (de)
DE (1) DE60329070D1 (de)
ES (1) ES2331414T3 (de)
WO (1) WO2003057733A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2233571B1 (de) * 2000-08-11 2012-11-07 Kyowa Hakko Kirin Co., Ltd. Den Phosphorsäure-Metabolismus, den Kalzium-Metabolismus, Verkalkung und den Vitamin D-Metabolismus kontrollierende Polypeptide sowie für diese kodierende DNA-Moleküle
JP4527982B2 (ja) 2001-12-28 2010-08-18 協和発酵キリン株式会社 線維芽細胞増殖因子−２３に対する抗体
WO2007011896A2 (en) * 2005-07-18 2007-01-25 The Trustees Of Boston University Method to inhibit proliferation and growth of metastases
WO2007126924A1 (en) * 2006-03-28 2007-11-08 University Of South Carolina Method for stimulating proteoglycan synthesis in cells
US20100062984A1 (en) * 2007-01-25 2010-03-11 Rajiv Kumar Fgf-23 polypeptides
US7883705B2 (en) 2007-02-14 2011-02-08 Kyowa Hakko Kirin Co., Ltd. Anti FGF23 antibody and a pharmaceutical composition comprising the same
WO2009133905A1 (ja) * 2008-04-28 2009-11-05 協和発酵キリン株式会社 ヒト線維芽細胞増殖因子23（ヒトfgf23)の作用を抑制するペプチドおよびそれを含む医薬組成物
ES2757591T3 (es) 2010-03-31 2020-04-29 Stabilitech Biopharma Ltd Estabilización de partículas virales
WO2011121301A1 (en) 2010-03-31 2011-10-06 Stabilitech Ltd Excipients for stabilising viral particles, polypeptides or biological material
US10422796B2 (en) 2010-08-31 2019-09-24 Kyowa Medex Co., Ltd. Method for measuring fibroblast growth factor-23 and reagent therefor
WO2012055096A1 (zh) * 2010-10-27 2012-05-03 温州医学院生物与天然药物开发中心有限公司 抗fgf-23抗体的制备方法及用途
TW201250248A (en) * 2011-04-25 2012-12-16 Kyowa Medex Co Ltd Prognostication method of renal failure
GB201117233D0 (en) * 2011-10-05 2011-11-16 Stabilitech Ltd Stabilisation of polypeptides
US20140273031A1 (en) * 2013-03-15 2014-09-18 The Cleveland Clinic Foundation In-vitro method for monoclonal antibody production
GB201406569D0 (en) 2014-04-11 2014-05-28 Stabilitech Ltd Vaccine compositions
MX381052B (es) 2014-06-09 2025-03-12 Ultragenyx Pharmaceutical Inc El control efectivo y eficaz del fosfato serico para una osificacion optima.
CN104502596A (zh) * 2014-12-23 2015-04-08 温州医科大学 一种慢性肾病诊断试剂盒
CN105699664A (zh) * 2015-04-13 2016-06-22 陈柏龄 Fgf23检测试剂盒及其制备方法
WO2016208776A1 (ja) 2015-06-25 2016-12-29 株式会社国際電気通信基礎技術研究所 多器官連関システムを基盤とした予測装置、及び予測プログラム
CL2015003047A1 (es) * 2015-10-15 2016-06-17 Univ Chile Método ex vivo para detectar precozmente injuria renal aguda en pacientes críticos, que comprende la mediciom en una muestra de tres proteinas como biomarcadores, factor de crecimiento fibroblástico 23, klotho y eritropoyetina
JP2019082329A (ja) * 2016-03-14 2019-05-30 協和メデックス株式会社 慢性腎臓病患者における高リン血症の発症のしやすさを試験する方法
JP6432962B2 (ja) 2016-03-29 2018-12-05 株式会社国際電気通信基礎技術研究所 腎機能低下、慢性腎疾患及び腎不全からなる群から選択される少なくとも一種の疾患を予防、又は治療するための有効成分の候補物質のスクリーニング方法
EP3466446B1 (de) * 2016-03-29 2023-12-27 Karydo Therapeutix, Inc. Pharmazeutische zusammensetzung oder nahrungsmittelzusammensetzung und verfahren zur beurteilung der wirkung eines wirkstoffs in vivo
GB2562241B (en) 2017-05-08 2022-04-06 Stabilitech Biopharma Ltd Vaccine compositions
WO2018221544A1 (ja) 2017-05-31 2018-12-06 協和メデックス株式会社 線維芽細胞増殖因子－２３の測定方法、測定試薬及び測定キット
WO2019026918A1 (ja) * 2017-08-01 2019-02-07 株式会社国際電気通信基礎技術研究所 皮膚のバイオマーカー
WO2021128065A1 (zh) * 2019-12-25 2021-07-01 广州菲康生物技术有限公司 人fgf-23的荧光免疫层析试纸和人fgf-23的荧光免疫层析检测试剂盒
CN119874901A (zh) * 2024-12-31 2025-04-25 上海良润生物医药科技有限公司 cFGF23特异性抗体及其在制备骨质疏松辅助诊断试剂中的应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985003934A1 (fr) 1984-03-06 1985-09-12 Takeda Chemical Industries, Ltd. Proteine modifiee chimiquement et son procede de preparation
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
FI884924L (fi) 1987-10-28 1989-04-29 Oncogen Humanimmuglobulin som producerats med hybrid-dna-teknik.
JP2958019B2 (ja) 1988-05-06 1999-10-06 住友製薬株式会社 ポリエチレングリコール誘導体、修飾ペプチドおよびその製造方法
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5958879A (en) * 1989-10-12 1999-09-28 Ohio University/Edison Biotechnology Institute Growth hormone receptor antagonists and methods of reducing growth hormone activity in a mammal
US6001358A (en) * 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
CN100359015C (zh) 1998-05-18 2008-01-02 伦敦大学专科学院 多肽激素磷酸盐沉着因子
TWI255853B (en) 1998-08-21 2006-06-01 Kirin Brewery Method for modifying chromosomes
AU3924300A (en) 1999-04-02 2000-10-23 Millennium Pharmaceuticals, Inc. Fibroblast growth factor-20
US6596849B1 (en) * 1999-05-28 2003-07-22 Academia Sinica Monoclonal-antibody for analysis and clearance of polyethylene glycol and polyethylene glycol-modified molecules
JP2004522402A (ja) 1999-06-02 2004-07-29 ジェネンテック・インコーポレーテッド 同一のものをコードする分泌及び膜貫通ポリペプチドと核酸
CA2491433A1 (en) 1999-12-01 2001-06-07 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP2003516150A (ja) 1999-12-08 2003-05-13 ジェンセット 潜在性分泌タンパク質をコードする全長ヒトｃＤＮＡ
EP1246843A1 (de) * 2000-01-05 2002-10-09 ZymoGenetics, Inc. Neues fgf homolog zfgf12
AU2001239765A1 (en) 2000-02-14 2001-08-27 Smith Kline Beecham Corporation Novel compounds
US20060160181A1 (en) * 2000-02-15 2006-07-20 Amgen Inc. Fibroblast Growth Factor-23 molecules and uses thereof
AU3976701A (en) * 2000-02-15 2001-08-27 Amgen, Inc. Fibroblast growth factor-23 molecules and uses thereof
AU2001245535A1 (en) * 2000-03-08 2001-09-17 Chiron Corporation Human fgf-23 gene and gene expression products
WO2001066595A2 (en) * 2000-03-08 2001-09-13 Chiron Corporation Human fgf-23 gene and gene expression products
ATE461213T1 (de) 2000-07-19 2010-04-15 Advanced Res & Tech Inst Neuer fibroblastwachstumsfaktor (fgf23) und methoden zur verwendung
EP2233571B1 (de) * 2000-08-11 2012-11-07 Kyowa Hakko Kirin Co., Ltd. Den Phosphorsäure-Metabolismus, den Kalzium-Metabolismus, Verkalkung und den Vitamin D-Metabolismus kontrollierende Polypeptide sowie für diese kodierende DNA-Moleküle
CA2430013C (en) 2000-11-30 2011-11-22 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
WO2002076467A1 (en) 2001-03-22 2002-10-03 Genzyme Corporation Compositions and methods to regulate bone and mineral metabolism
US20040171825A1 (en) * 2001-04-26 2004-09-02 Lydie Bougueleret Human fibroblast growth factor-related compositions
JP4527982B2 (ja) 2001-12-28 2010-08-18 協和発酵キリン株式会社 線維芽細胞増殖因子−２３に対する抗体
US7094551B2 (en) * 2002-09-17 2006-08-22 Zahradnik Richard J Immunoassays, assay methods, antibodies and method of creating antibodies for detecting FGF-23
JPWO2006078072A1 (ja) 2005-01-21 2008-06-19 キリンファーマ株式会社 キメラ非ヒト動物およびその使用
US20100062984A1 (en) 2007-01-25 2010-03-11 Rajiv Kumar Fgf-23 polypeptides
US7883705B2 (en) * 2007-02-14 2011-02-08 Kyowa Hakko Kirin Co., Ltd. Anti FGF23 antibody and a pharmaceutical composition comprising the same

Also Published As

Publication number Publication date
KR20040073518A (ko) 2004-08-19
EP1466925A4 (de) 2006-01-04
ES2331414T3 (es) 2010-01-04
EP1466925A1 (de) 2004-10-13
US7923012B2 (en) 2011-04-12
DE60329070D1 (de) 2009-10-15
AU2003202472A1 (en) 2003-07-24
AU2003202472B2 (en) 2009-11-26
CN100519584C (zh) 2009-07-29
HK1078093A1 (zh) 2006-03-03
EP1466925B1 (de) 2009-09-02
US20050048058A1 (en) 2005-03-03
CN1639193A (zh) 2005-07-13
JP4527982B2 (ja) 2010-08-18
CA2471656C (en) 2012-07-31
WO2003057733A1 (fr) 2003-07-17
KR101016476B1 (ko) 2011-02-24
CA2471656A1 (en) 2003-07-17
JPWO2003057733A1 (ja) 2005-05-19

Similar Documents

Publication Publication Date Title
ATE441666T1 (de) Antikírper gegen den fibroblastenwachstumsfaktor 23
IL210455A0 (en) Novel cytokine zcytor17 ligand
ATE263778T1 (de) Niedrigallergene proteinvarianten
PT839196E (pt) Ctla-8 humana e utilizacoes de proteinas relacionadas com ctla-8
NO20074516L (no) Pattedyrcytokinlignende polypeptid-1
DK1114156T3 (da) Transformerende vækstfaktor Beta-9 (ZTGFSS9) fra pattedyr
WO2002061076A1 (fr) Proteine associee a l'adiponectine
ATE403726T1 (de) Cytokin-proteinfamilie
CA2441187A1 (en) Acetyllysine-recognizing monoclonal antibody and process for producing the same
AU2003202489A1 (en) Screening method
EP1295943A4 (de) Polypeptide mit aktivität der stimulierung von neutrophilen
DE69941961D1 (de) Monoklonale Antikörper gegen humane Thymidylat-Synthase und Hybridomen zu derer Herstellung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties